文献速递传染病防控与疫情报告免疫规划

LVD/NIAID/NIH MVA1974克隆株作为猴痘疫苗——小鼠致死性正痘病毒猴痘感染模型的临床前评估

The LVD/NIAID/NIH MVA1974 clone as an Mpox vaccine - preclinical assessment upon in a model of lethal infection with Orthopoxvirus monkeypox in mice.
PubMed 文献 · Vaccine · 2025-10-26

研究评估了此前未针对猴痘测试的LVD/NIAID/NIH MVA1974克隆株在小鼠模型中的免疫原性和保护效力。小鼠经肌肉注射1×10^8 FFU MVA1974并以初免-加强方案免疫,诱导了强健免疫应答,并对致死性MPXV攻击提供完全(100%)保护。鉴于全球需求增长而获批MVA疫苗短缺,MVA1974等替代克隆株是有望进一步开发为猴痘疫苗的候选。

要点

  • 小鼠肌肉注射1×10^8 FFU MVA1974、初免-加强方案,诱导强健免疫应答。
  • 免疫对致死性MPXV攻击提供完全(100%)保护。
  • 全球获批MVA疫苗短缺,MVA1974等替代克隆株是有望进一步开发的候选。

核心结论

  • MVA1974克隆株在小鼠中诱导强健免疫应答,并对致死性MPXV攻击提供完全(100%)保护。
  • 鉴于获批MVA疫苗短缺而全球需求增长,MVA1974等替代MVA克隆株是有望进一步开发为猴痘疫苗的候选。

研究设计与样本

  • 研究在小鼠模型中评估LVD/NIAID/NIH MVA1974克隆株的免疫原性和保护效力,该克隆株此前未针对猴痘测试。
  • 小鼠经肌肉注射1×10^8 FFU MVA1974,采用初免-加强方案免疫。

主要发现

  • 免疫诱导强健免疫应答,并对致死性MPXV攻击提供完全(100%)保护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monkeypox virus (MPXV), a genetically distinct member of the Orthopoxvirus genus, causes a febrile vesicular illness in humans and animals, recently renamed Mpox. In 2022, Mpox cases were reported in 115 non-endemic countries, prompting the World Health Organization (WHO) to declare a Public Health Emergency of International Concern. A resurgence of cases in August 2024, centered in the Democratic Republic of Congo and neighboring regions, led to renewed international concern. The Modified Vaccinia Ankara (MVA) virus, originally developed as a safer smallpox vaccine, has demonstrated protective efficacy against MPXV. However, only a limited number of MVA clones have been evaluated or produced specifically for Mpox prevention. In this study, we assessed the immunogenicity and protective efficacy of the LVD/NIAID/NIH MVA1974 clone-previously untested for Mpox-in a mouse model. Mice were immunized intramuscularly with 1 × 108 FFU of the MVA1974 virus using a prime-boost regimen. Immunization induced robust immune responses and provided complete (100 %) protection against a lethal MPXV challenge. Given the current shortage of approved MVA-based vaccines amid growing global demand, alternative MVA clones such as MVA1974 represent promising candidates for further development as Mpox vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lourenço KL, Oliveira Paim AA, Hojo-Souza NS, et al. The LVD/NIAID/NIH MVA1974 clone as an Mpox vaccine - preclinical assessment upon in a model of lethal infection with Orthopoxvirus monkeypox in mice. Vaccine. 2025. PMID: 41145076. doi:10.1016/j.vaccine.2025.127889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。